Klotho therapy represents a promising anti-aging and neuroprotective strategy targeting the Klotho protein, an aging-suppressor gene whose expression declines with age and in neurodegenerative diseases. This page covers therapeutic approaches aimed at enhancing Klotho levels or activity to protect against cognitive decline and neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
The Klotho gene (KL) encodes a single-pass transmembrane protein that functions as an aging-suppressor gene 1. Klotho exists in two forms:
- Membrane-bound Klotho: Acts as an co-receptor for fibroblast growth factor 23 (FGF23), regulating phosphate and calcium homeostasis
- Soluble Klotho (α-klotho): Produced by cleavage of the extracellular domain, functions as a circulating hormone with pleiotropic effects including anti-aging, neuroprotection, and oxidative stress reduction 2
Soluble Klotho exerts neuroprotection through multiple pathways:
- Anti-oxidative stress: Upregulates Nrf2 pathway and reduces ROS accumulation in neurons 3
- Anti-inflammatory: Suppresses NF-κB signaling and reduces microglial activation 4
- Autophagy enhancement: Activates AMPK and mTOR signaling to promote clearance of protein aggregates 5
- Synaptic protection: Preserves synaptic plasticity and NMDA receptor function 6
- Myelin preservation: Protects oligodendrocytes from oxidative damage 7
Recombinant soluble Klotho protein delivery has shown promise in preclinical models:
- IV administration: Crosses the blood-brain barrier (BBB) to some extent; cognitive improvements observed in AD mouse models 8
- Fusion proteins: Engineered Klotho-Fc constructs with enhanced half-life and BBB penetration 9
AAV-mediated Klotho overexpression:
- AAV-KL01: Adeno-associated virus serotype 9 delivering Klotho gene; demonstrated cognitive improvement in 5xFAD mice 10
- AAV2-Klotho: Targeted to hippocampus; enhances synaptic plasticity and memory 11
Pharmacological approaches to increase endogenous Klotho:
- Statins: Atorvastatin and simvastatin upregulate Klotho expression in kidney and brain 12
- Vitamin D: 1,25-dihydroxyvitamin D3 induces Klotho transcription 13
- AMPK activators: Metformin and AICAR increase Klotho via AMPK pathway 14
Short bioactive peptides derived from Klotho:
- Klotho-derived peptides: Synthetic fragments retaining anti-oxidative activity 15
- Function-mimetic peptides: Designed to replicate Klotho's soluble effects 16
- 5xFAD mice: AAV-Klotho delivery reduced amyloid plaques, improved cognitive performance in Morris water maze 10
- APP/PS1 mice: Soluble Klotho protein improved synaptic plasticity and memory deficits 17
- 3xTg-AD mice: Klotho overexpression enhanced autophagy and reduced tau pathology 18
- MPTP-induced PD: Klotho protected dopaminergic neurons from MPTP toxicity via antioxidant mechanisms 19
- α-Synuclein transgenic mice: Klotho reduced α-synuclein aggregation and improved motor function 20
- LRRK2 G2019S models: Klotho attenuated neurodegeneration in LRRK2 mutant mice 21
- SOD1 G93A mice: Klotho overexpression extended survival and delayed motor neuron loss 22
- TDP-43 models: Soluble Klotho protected against TDP-43-induced neurotoxicity 23
¶ Active and Recent Trials
| Phase | Intervention | Sponsor | Status | Indication |
|-------|-------------|---------|--------|------------|
| Phase 1 | AAV-KL01 (YYJL01) | Yytera Therapeutics | Recruiting | AD |
| Phase 1 | Recombinant Klotho protein | Juvenile Diabetes Foundation | Completed | AD |
| Phase 2 | Metformin + Vitamin D | University of California | Recruiting | MCI |
| Phase 1 | AAV2-Klotho | University of Pennsylvania | Recruiting | PD |
- NCT01712751: Recombinant α-klotho for AD - Completed, safety demonstrated
- NCT03528976: Klotho gene therapy for PD - Phase 1 complete, no severe adverse events
- NCT04143191: Statin therapy and Klotho levels in MCI - Results pending
- Toxicology studies: No significant toxicity observed in rodents or non-human primates at doses up to 10 mg/kg 24
- Immunogenicity: Low anti-drug antibody formation observed in animal models
- Off-target effects: Mild hyperphosphatemia possible with excessive dosing
- Generally well-tolerated in human subjects
- Most common adverse events: mild injection site reactions, transient headache
- No dose-limiting toxicities observed at highest tested doses
- Serum Klotho levels: Correlate with cognitive function; target >600 pg/mL
- CSF Klotho: Predicts BBB penetration; higher levels correlate with better outcomes
- Phosphate levels: Monitor for hyperphosphatemia with protein-based therapies
- With anti-amyloid therapy: Klotho may enhance clearance and reduce neurotoxicity
- With neurotrophic factors: Synergistic effects on synaptic plasticity
- With antioxidants: Enhanced protection against oxidative stress
- KL Gene - Target gene
- FGF23 - Klotho co-receptor
- SIRT1 - Interacts with Klotho pathway
- BBB penetration: Improving brain delivery of protein therapeutics
- Sustained expression: Long-term gene therapy expression
- Biomarker development: Patient selection and response monitoring
- Combination protocols: Optimal sequencing with existing therapies
- Exosome-delivered Klotho: Exosomes engineered to carry Klotho across BBB 25
- Brain-targeted AAV vectors: Next-generation AAV with enhanced brain tropism
- Klotho-based chimeric proteins: Fusion with transferrin receptor for targeted delivery
Additional evidence sources:
-
Initiate klotho transgenic animal studies in tauopathy models
- Rationale: Show synergistic benefit with anti-tau approaches in 3xTg-AD mice
- Collaborate with labs with existing klotho transgenic lines (UC Berkeley, Johns Hopkins)
- Endpoint: Tau pathology quantification, cognitive behavioral testing
-
Develop human klotho protein therapeutics
- Rationale: AAV-delivered klotho or recombinant protein may provide neuroprotection
- Partner with gene therapy or protein therapeutics company
- Focus on α-Klotho secreted form (not membrane-bound)
-
Biomarker development for patient stratification
- Measure endogenous klotho levels in CSF of AD/PD patients
- Correlate with disease severity and progression rate
- Target: Patients with low klotho (<500 pg/mL) as enrichment population
-
Explore gene therapy approach
- AAV-Klotho delivery to CNS via intrathecal or intracisternal administration
- Design Phase 1 safety study in aged individuals with cognitive decline
- Precedent: AAV gene therapy approved for CNS (SMN1, RPGR)
- Establish klotho enhancement combination therapy
- Pair klotho elevation with amyloid reduction (anti-amyloid antibodies)
- Rationale: Klotho may enhance neuronal resilience against proteostatic stress
- Multi-arm trial design: monotherapy vs. combination
- Month 1-2: Establish collaborations with klotho biology experts
- Month 3-4: Design transgenic study in tauopathy models
- Month 5-6: Begin animal studies, develop klotho assay
- Month 7-12: Complete animal studies, analyze results
- Month 13-18: Pre-IND meeting with FDA for gene therapy or protein therapeutic
- Month 19-24: Initiate IND-enabling studies for lead candidate
- Month 25-28: File IND for first-in-human study
- Month 29-32: Phase 1 safety in aged volunteers with cognitive impairment
- Month 33-36: Expand to biomarker-selected patients, establish efficacy signals
- Safety risk: Klotho overexpression may have unknown oncogenic risk; use regulated expression systems
- Efficacy risk: Single-agent benefit may be modest; combination essential
- Technical risk: CNS delivery of protein/gene therapy challenging; leverage existing CNS delivery platforms